Search Results for: multaq

Heart Society’s Tip Sheets Fail To Mention Risks

Editor’s note: The following post is reprinted with permission from ProPublica. It is the latest installment in ProPublica’s Dollars for Doctors: How Industry Money Reaches Physicians, an ongoing investigation. Heart Society’s Tip Sheets Fail To Mention Risks by Charles Ornstein and Tracy Weber ProPublica, May 5, 2011, 9:48 p.m. For patients researching solutions for scary,…

Click here to continue reading…

Financial Ties Bind Medical Societies To Drug and Device Makers

Editor’s note: The following post is reprinted with permission from ProPublica. It is the latest installment in ProPublica’s Dollars for Doctors: How Industry Money Reaches Physicians, an ongoing investigation. Financial Ties Bind Medical Societies To Drug and Device Makers by Charles Ornstein and Tracy Weber ProPublica, May 5, 2011, 9:48 p.m. This story has been…

Click here to continue reading…

Study Estimates That AF Adds $26 Billion to Yearly US Healthcare Costs

Atrial fibrillation adds $26 billion to the nation’s healthcare bill, according to a study published in  Circulation: Cardiovascular Quality and Outcomes. Michael Kim and colleagues compared insurance claims for one year from 89,066 AF patients to a group of controls matched for gender, age, and other medical conditions and found that AF results in a…

Click here to continue reading…

Some Remaining Questions About Dabigatran

Yesterday’s approval of dabigatran (Pradaxa) has been long awaited in the cardiology community. Although just about everyone agrees that a good alternative to warfarin is highly desirable, there are many remaining questions about the drug as it prepares to enter the marketplace. Here are a few questions raised by electrophysiologist John Mandrola on his blog:…

Click here to continue reading…

Guest Post: Big Pharma Knows Your Private Health Matters

(Editor’s note: The following post is written by Dr. John Mandrola, an electrophysiologist in Louisville, KY. Mandrola is also the author of his own blog, Dr John M, where this post originally appeared.) by Dr. John Mandrola He was here for routine follow-up. He has atrial fibrillation. He is, and has been well controlled on…

Click here to continue reading…

Dronedarone and ticagrelor speed into ESC guidelines

Getting into the guidelines can be a slow and laborious process. Some critics complain that it takes too long for new therapies to receive the guideline seal of approval. But with the new guidelines released at the ESC it’s unlikely that anyone will complain about such dawdling. With unprecedented speed, dronedarone  and ticagrelor have achieved…

Click here to continue reading…

Can we trust ATHENA?

I’ve written extensively on CardioBrief about Sanofi’s promotion of Multaq (dronedarone). John Fauber, a reporter for the Journal Sentinel in Milwaukee, tackles the topic from an important perspective that often gets ignored or neglected. He focuses on ATHENA, the drug’s pivotal trial, and notes that all the trial authors had financial ties to Sanofi. Further,…

Click here to continue reading…

Guest Post: Steve Nissen and Jack Lewin debate interactions with industry

Editor’s Note: The following guest post was written by Marilyn Mann, a lawyer with a keen interest in health policy. Members of her family have familial hypercholesterolemia (and have been treated by Steve Nissen), which may account for her particular interest in cardiology and this debate. Last week I attended the American Heart Association Quality…

Click here to continue reading…

Prystowsky lecture resurfaces, this time with COI disclosures

It’s back. This time with a disclosure of conflicts of interest. The Eric Prystowsky lecture that was the only piece of original content on AFibProfessional.org, the Sanofi-sponsored website run under the auspices of the ACC and HRS, is back on the site once again after being removed last week after a critical story was published here on CardioBrief….

Click here to continue reading…

Dronedarone approved by FDA for atrial fibrillation or atrial flutter

Following a contentious FDA advisory panel meeting and considerable discussion about the ultimate clinical role of the drug, dronedarone (Multaq) has finally been approved by the FDA for the treatment of atrial fibrillation or atrial flutter. Sanofi-Aventis said it planned to launch the drug this summer. According to the FDA, the drug’s label will contain…

Click here to continue reading…

Dronedarone gets cautious nod from FDA advisory panel

The FDA’s Cardiovascular and Renal Advisory Committee voted 10 to 3 in favor of approval for Sanofi’s dronedarone. By all accounts it was a difficult decision for the committee. CardioBrief has received statements from panel members Sanjay Kaul (yes, he did make it to the meeting) and Darren McGuire….

Click here to continue reading…